Industry News: BioProcess International European Conference and Exhibition

10 Apr 2007

During the past 26 years Amgen has grown from a start-up organisation to a fully integrated biopharmaceutical company of almost 20,000 with sales of over $12B annually. So how did it get to where it is today?

This is a challenge that many biopharmaceutical companies strive to achieve. How Amgen overcame these challenges which resulted in its prominent growth, are explained by Dr James Thomas, the Vice President in the Process and Analytical Sciences Department in the USA. He will place a special emphasis on how the company has created both a rich pipeline and the commercial infrastructure required to get products into the hands of patients.

You can hear Dr James Thomas present his view on the challenges Amgen has faced at this years BioProcess International European Conference 24th April 2007, He is a plenary speaker on Day 1 at 9.05.

For more information please visit the article webpage.